Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zai Lab Limited - American Depositary Shares (NQ:ZLAB)

23.32 +2.44 (+11.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Zai Lab Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >
News headline image
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Zai Lab Limited Investors to Inquire About Securities Class Action Investigation - ZLAB
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Zai Lab Limited Investors to Inquire About Securities Class Action Investigation - ZLAB
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ROSEN, A LEADING LAW FIRM, Encourages Zai Lab Limited Investors to Inquire About Securities Class Action Investigation - ZLAB
WHY: New York, NY - (NewMediaWire) - July 02, 2023 - Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zai Lab... 
Via NewMediaWire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Hayward and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Announces NDA Acceptance of Repotrectinib for Patients with ROS1-positive NSCLC by China’s NMPA
From Zai Lab Limited
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Zai Lab, Hayward, Ascendis, and Alvotech and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ZLAB LOSS ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Zai Lab Limited Investors to Inquire About Securities Class Action Investigation - ZLAB
WHY: New York, NY - (NewMediaWire) - June 23, 2023 - Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zai Lab... 
Via NewMediaWire
News headline image
ZAI LAB ALERT: Bragar Eagel & Squire, P.C. is Investigating Zai Lab Limited on Behalf of Zai Lab Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
News headline image
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Zai Lab Limited Investors with Losses to Inquire About Securities Class Action Investigation - ZLAB
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
ZLAB INVESTOR NEWS: ROSEN, A LEADING LAW FIRM, Encourages Zai Lab Limited Investors with Losses to Inquire About Securities Class Action Investigation – ZLAB
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
EQUITY ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Zai Lab Limited Investors with Losses to Inquire About Securities Class Action Investigation – ZLAB
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual Meeting
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Announces Participation in June Investor Conferences
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Announces That Repotrectinib Granted Priority Review by China’s NMPA
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Announces First Quarter 2023 Financial Results and Corporate Updates
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Announces Strategic Partnership and Global License Agreement with MediLink Therapeutics for a Next Generation Antibody-Drug Conjugate Program in Oncology
YL212 expands Zai Lab’s lung cancer franchise and enriches its global oncology pipeline with a potential first-in-class ADC 
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab to Announce First Quarter 2023 Financial Results and Corporate Updates on May 9, 2023
Company to Host Conference Call and Webcast on May 10, 2023, at 8:00 a.m. ET 
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab to Highlight New Data from its Oncology Portfolio at 2023 AACR Annual Meeting
New translational and clinical biomarker data from Zai Lab’s global oncology program ZL-1211 will be featured in a poster presentation (Abstract presentation number: 4531) 
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Announces Full-Year 2022 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Announces Participation in March Investor Conferences
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the 2023 ESMO Gynaecological Cancers Congress
From Zai Lab Limited
Via GlobeNewswire
News headline image
3 More Mid-Cap Biotechs The Street Sees Doubling
According to Wall Street research groups, these three mid-cap biotechs have 2x potential. It’s for the investor to decide if the upside justifies the risk. 
Via MarketBeat
News headline image
Zai Lab Announces NDA Acceptance of Sulbactam-Durlobactam (SUL-DUR) for Infections Caused by Acinetobacter baumannii in China by the NMPA
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2023
Company to Host Conference Call and Webcast on March 2, 2023, at 8:00 a.m. ET 
From Zai Lab Limited
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.